Investigating T Cell Egress via Lymphatic Vessels in Melanoma
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
批准号:
10563146
负责人:
Amanda W. Lund
金额:
$38.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-02-28
关键词:
AffinityAntibodiesAntigensAutomobile DrivingBiologicalBiological MarkersBiological ModelsCD8-Positive T-LymphocytesCTLA4 geneCXCR4 geneCXCR6 geneCell CountCellsClinicalCytotoxic T-LymphocytesDataFutureG-Protein-Coupled ReceptorsHeterogeneityHomingImmuneImmune EvasionImmunosuppressionImmunotherapyIn SituInterferon Type IILabelLeukocytesLigandsLymphaticLymphocyteMediatingMetabolismMetastatic MelanomaMolecularMusMutationNeoplasm MetastasisPD-1/PD-L1Pathway interactionsPatientsPlayPopulationPre-Clinical ModelPredispositionProteinsPublishingResistanceResolutionRoleRouteSignal TransductionSpecificityStromal Cell-Derived Factor 1T cell infiltrationT-Cell ActivationT-LymphocyteTestingTherapeuticTimeTissuesTransgenic MiceTransgenic OrganismsTumor AntigensTumor EscapeTumor ExpansionTumor ImmunityWorkanti-tumor immune responsecancer carecandidate identificationchemokinechemokine receptorclinical efficacyclinical translationclinically actionablecytotoxic CD8 T cellseffector T cellexhaustionimmune checkpointimmune checkpoint blockadeimprovedin vivolymphatic vasculaturelymphatic vesselmelanomanovelnovel strategiespatient stratificationpreventrecruitresidenceresponsesynergismtargeted agenttargeted treatmenttreatment responsetumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The clinical efficacy of immune checkpoint blockade (ICB) in a subset of metastatic melanoma patients has
catalyzed a revolution in cancer care leading to its application to a variety of other tumor types. The
discrepancy in response to ICB between, and even within, tumor types, however, indicates that additional
mechanisms of suppression must be targeted to expand utility of these therapies. Recent biomarker studies,
indicate that presence of cytotoxic T cells (CTLs) within tumor microenvironments enriches for patients who are
likely to respond, suggesting that efforts to improve intratumoral accumulation of tumor-specific CTLs might
enhance response to therapy. The current proposal will examine mechanisms regulating T cell exit from
melanoma and propose inhibition of egress as a novel strategy to improve T cell retention and thus response
to ICB. We will test the hypothesis that tumor-associated lymphatic vessels influence intratumoral CTL pools
by directing their egress. Transgenic mice expressing a photoconvertible protein will be used to in situ label
and in vivo track tumor resident lymphocyte populations. Using this model system paired with transgenic T
cells and altered antigen ligands, we will determine the role antigen encounter plays in determining which cells
egress from melanoma microenvironments to delineate how T cell egress from tumors contributes to the
diversity of the intratumoral T cell repertoire. Our preliminary data indicates that T cells specific for tumor
antigens egress from tumors indicating that inhibition of tumor exit, to retain these T cells, might improve
response to immunotherapy. To test this, we will determine the functional significance of candidate chemokine
receptors, CXCR4 and CXCR6, which we predict regulate T cell egress and retention respectively. We will
determine the therapeutic synergy of combining agents targeting these pathways with immune checkpoint
blockade. Finally, we have shown that disrupting lymphatic vessel crosstalk with CTLs, mediated by IFNγ,
improves tumor control. We will explore the role of IFNγ-mediated bidirectional crosstalk in regulating T cell
egress through lymphatic vessels and thus propose T cell egress as a mechanism of immune resolution
coopted by tumor microenvironments to mediate immune evasion. Taken all together, we propose that CTLs
integrate multiple signals in melanoma microenvironments that tune their accumulation and function in concert
with the lymphatic vasculature. We predict that inhibition of CTL egress represents a tractable clinical strategy
that can synergize with therapies targeting additional immunosuppressive mechanisms (e.g. metabolism and
exhaustion), and mechanistic studies described herein will provide the rationale for future clinical translation.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Be Easy and Chill: Melanoma Cells Tell Lymph Node Fibroblasts to Relax.
放松心情:黑色素瘤细胞告诉淋巴结成纤维细胞放松。
DOI:
10.1158/0008-5472.can-22-0940
发表时间:
2022
期刊:
Cancer research
影响因子:
11.2
作者:
[Lund,AmandaW]
通讯作者:
Lund,AmandaW
Lymph node metastasis fuels systemic disease.
淋巴结转移会加剧全身性疾病。
DOI:
10.1016/j.trecan.2022.06.003
发表时间:
2022
期刊:
Trends in cancer
影响因子:
18.4
作者:
[Ventre,KatherineS, Karakousi,Triantafyllia, Lund,AmandaW]
通讯作者:
Lund,AmandaW
DOI:
10.1084/jem.20230904
发表时间:
2023-09-04
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
[]
通讯作者:
Lymph: (Fe)rrying Melanoma to Safety.
淋巴:将黑色素瘤转移到安全的地方。
DOI:
10.1016/j.ccell.2020.08.011
发表时间:
2020
期刊:
Cancer cell
影响因子:
50.3
作者:
[Lund,AmandaW, Soengas,MariaS]
通讯作者:
Soengas,MariaS
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma Progression
-
批准号:10414446
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2022
-
负责人:Amanda W. Lund
-
依托单位:
Dermal Lymphatic Transport and Cutaneous Immune Balance
-
批准号:10339645
-
项目类别:
-
资助金额:$44.02万
-
财政年份:2022
-
负责人:Amanda W. Lund
-
依托单位:
Dermal Lymphatic Transport and Cutaneous Immune Balance
-
批准号:10573219
-
项目类别:
-
资助金额:$44.02万
-
财政年份:2022
-
负责人:Amanda W. Lund
-
依托单位:
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma Progression
-
批准号:10705088
-
项目类别:
-
资助金额:$36.57万
-
财政年份:2022
-
负责人:Amanda W. Lund
-
依托单位:
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
-
批准号:10162542
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2020
-
负责人:Amanda W. Lund
-
依托单位:
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
-
批准号:10116838
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2020
-
负责人:Amanda W. Lund
-
依托单位:
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
-
批准号:10334541
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2020
-
负责人:Amanda W. Lund
-
依托单位:
海外基金